Ginkgo Bioworks Holdings Inc (NYSE:DNA) has a beta value of 1.11 and has seen 0.51 million shares traded in the recent trading session. The company, currently valued at $676.20M, closed the recent trade at $11.76 per share which meant it gained $0.11 on the day or 0.98% during that session. The DNA stock price is -447.62% off its 52-week high price of $64.40 and 55.27% above the 52-week low of $5.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.47 million shares traded. The 3-month trading volume is 1.22 million shares.
The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is Buy stock at the moment, with a recommendation rating of 3.83. 2 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Sporting 0.98% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the DNA stock price touched $11.76 or saw a rise of 7.76%. Year-to-date, Ginkgo Bioworks Holdings Inc shares have moved 19.80%, while the 5-day performance has seen it change 24.62%. Over the past 30 days, the shares of Ginkgo Bioworks Holdings Inc (NYSE:DNA) have changed 21.66%. Short interest in the company has seen 7.17 million shares shorted with days to cover at 4.67.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could drop -68.0% from the levels at last check today.. The projected low price target is $7.0 while the price target rests at a high of $7.0. In that case, then, we find that the latest price level in today’s session is 40.48% off the targeted high while a plunge would see the stock lose 40.48% from the levels at last check today..
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Figures show that Ginkgo Bioworks Holdings Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -4.70% over the past 6 months, with this year growth rate of 35.77%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be -9.45%.
5 analysts offering their estimates for the company have set an average revenue estimate of 44.43M for the current quarter. 4 have an estimated revenue figure of 44.24M for the next ending quarter. Year-ago sales stood 34.76M and 37.94M respectively for this quarter and the next, and analysts expect sales will grow by 27.83% for the current quarter and -9.45% for the next.
Earnings growth for 2025 is a modest 45.22% while over the next 5 years, the company’s earnings are expected to increase by 31.20%.
DNA Dividends
Ginkgo Bioworks Holdings Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Insiders own 6.68% of the company shares, while shares held by institutions stand at 68.36% with a share float percentage of 73.26%. Investors are also buoyed by the number of investors in a company, with Ginkgo Bioworks Holdings Inc having a total of 228.0 institutions that hold shares in the company. The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 143.09 million shares worth more than $47.83 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 7.1383% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 138.96 million shares as of 2024-06-30. The firm’s total holdings are worth over $46.46 million and represent 6.9327% of shares outstanding.
